Loading...
OTCM
INFIQ
Market cap0kUSD
Mar 11, Last price  
0.00USD
Name

Infinity Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.04%
Rev. gr., 5y
-15.45%
Revenues
3m
+39.56%
49,826,59251,564,04834,836,97718,494,55824,536,35083,440,66649,538,71471,330,98792,773,16247,114,0000164,995,000109,066,00018,723,0006,000,00022,146,0003,049,0001,719,0001,858,0002,593,000
Net income
-43m
L-4.81%
1,058,9133,902,772-14,164,737-28,447,973-16,897,88723,654,357-32,505,265-48,983,659-40,042,101-53,964,000-126,780,000-17,416,000-128,376,000-30,101,000-41,830,000-11,253,000-47,057,000-42,937,000-45,442,000-43,256,000
CFO
-42m
L+4.46%
8,127,3864,749,9746,056,5759,655,70712,082,295-10,422,417-4,756,922-26,585,050-33,108,955-80,135,000-113,907,000117,715,000-83,653,000-154,356,000-36,711,000-4,714,000-41,530,000-35,739,000-40,618,000-42,431,000

Profile

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
URL
https://www.infi.com/
IPO date
Jul 27, 2000
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,593
39.56%
Cost of revenue
47,437
Unusual Expense (Income)
NOPBT
(44,844)
NOPBT Margin
Operating Taxes
(1,113)
Tax Rate
NOPAT
(43,731)
Net income
(43,256)
-4.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
73
BB yield
-0.15%
Debt
Debt current
593
Long-term debt
648
Deferred revenue
Other long-term liabilities
47,250
Net debt
(37,072)
Cash flow
Cash from operating activities
(42,431)
CAPEX
(17)
Cash from investing activities
(55)
Cash from financing activities
73
FCF
(42,226)
Balance
Cash
38,313
Long term investments
Excess cash
38,183
Stockholders' equity
(855,863)
Invested Capital
884,979
ROIC
ROCE
EV
Common stock shares outstanding
89,248
Price
0.56
-75.33%
Market cap
49,533
-74.28%
EV
12,461
EBITDA
(44,386)
EV/EBITDA
Interest
180
Interest/NOPBT